CD19 and breast cancer: With solid tumors (Figure 16A), the strongestcorrelation is between breast cancer and HER2 as target antigen, whileamong hematological malignancies (Figure 16B) lymphoma correlates strongly and comparablywith CD19, CD22, and CD30, leukemia–with CD33 and CD19, andmyeloma, with BCMA.